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ABSTRACT
Objective: The objective of the study was to assess and compare the efficacy and tolerability of flupirtine versus tramadol in patients with chronic 
moderate low back pain (LBP).
Materials and Methods: A prospective study was conducted in the outpatient department of orthopaedics at tertiary care hospital, Rajamahendravarm. 
After meeting the inclusion criteria, a total of 60 patients were randomly allocated to tablet flupirtine 100 mg in Group A and tablet tramadol 50 mg 
in Group B. The efficacy of the study drugs was assessed at baseline and the end of treatment by numerical rating scale11, visual analog scale-100 mm, 
physician’s, and patient’s global assessment. Statistical analysis was done using paired and unpaired t-test and data were presented as mean±standard 
deviation. Adverse drug reactions were monitored during the treatment.
Results: The study results showed that 90% of the patients in Group A and 78% of the patients in Group B had shown a good response to their 
respective drugs. 30% of flupirtine group patients reported adverse drug reactions which were mild.
Conclusion: Both the drugs are effective in the treatment of moderate chronic LBP, but the advantage of flupirtine was, the incidence of adverse drug 
reactions was less when compared to tramadol group.
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INTRODUCTION
Low back pain (LBP) is the major health problem worldwide and it 
is the fifth most common reason for a physician visit, in which nearly 
60–80 % of people are affected throughout their lifetime, and the 
prevalence of chronic LBP is 23% [1,2]. In chronic LBP, 90% of cases 
were non-specific, whereas 5–10% of cases were specific in origin, 
like degenerative conditions, inflammation, infection, and neoplasm. 
Studies have reported that the prevalence of chronic LBP is increasing 
linearly from the third decade of life to 60 years of age, and more 
common in women [3]. LBP is a leading cause of activity limitation 
and work absence which has a huge impact on economic burden [4], 
so medications are recommended to keep patients physically active 
and to restore functional abilities and participation in daily life [1]. The 
pharmacological agents prescribed for chronic LBP are nonsteroidal 
anti-inflammatory drugs (NSAIDs), skeletal muscle relaxants, 
benzodiazepines, systemic corticosteroids, and opioid analgesics [5]. 
At present, the mainstay of the treatment for chronic LBP is NSAIDs 
and opioids, but long-term use of these drugs cause gastrointestinal 
tract disturbances and sedation. Flupirtine maleate is a centrally-
acting and non-opioid analgesic. It is unique among analgesics as it 
has dual therapeutic effects such as analgesic and muscle relaxant 
properties. Flupirtine is a selective neuronal potassium channel opener 
(SNEPCO) which activates G-protein-coupled receptors that stimulate 
K+ channels of neuronal cells and it also indirectly acts as N-methyl-
D-Aspartate (NMDA) antagonist and inhibits neuronal excitability and 
reduces calcium Ca2+ influx into the cells. This mechanism is vital for 
neuronal transmission of pain signals to motor neurons [6]. Flupirtine 
has shown mild adverse effects such as a headache, dizziness, nausea, 
and epigastric complaints and there were no serious adverse events 
(SAE) and no signs of drug dependence, tolerance, or withdrawal 
symptoms. A multicenter phase IV study conducted in Germany had 
shown that tolerability of flupirtine treatment was excellent with 
extremely low withdrawal and adverse event rates [7]. On the other 
hand, standard drug, tramadol is an atypical centrally acting opioid 
analgesic, most commonly used for pain relief, its analgesic effect is 
exerted by a dual mechanism, by weak µ opioid agonist and also acts 
by inhibiting reuptake of serotonin and norepinephrine (NE) [8,9].
Although both flupirtine and tramadol individually have proven their 
efficacy in the treatment of moderate chronic LBP; however, there is a 
paucity of studies comparing both the drugs. Hence, the present study 
was carried out to assess the efficacy and tolerability of flupirtine and 
tramadol in chronic LBP of moderate intensity.
MATERIALS AND METHODS
This was a prospective, randomized study conducted on 60 patients 
suffering from chronic LBP, who attended the Outpatient Department 
of Orthopaedics at GSL Medical College and General Hospital, 
Rajamahendravaram, Andhra Pradesh, India. After getting approval 
from the Institutional Ethics Committee, all the study subjects who 
were enrolled in the study are screened by physician and orthopedician 
followed by an examination. Informed and written consent was taken 
from the study subjects who are satisfying the selection criteria. The 
selection criteria included patients between the ages of 20 and 60 years 
with nonspecific LBP for >3 months duration. Exclusion criteria were 
patients with a history of hepatic or renal disease, major trauma, cancer, 
infection, cauda equina syndrome, fibromyalgia, osteoporosis, or 
vertebral compression. Pregnant and lactating women and those with a 
history of hypersensitivity to these drugs were also excluded from the 
study. After initial screening, the demographic data, history, drug history, 
family history, findings of general and physical examination, and blood 
investigations (liver function test and renal parameters) were recorded 
in case record form. The study subjects were randomly divided into two 
Groups A and B by computer-based technique. Group A was allocated 
with tablet flupirtine 100 mg and Group B with tablet tramadol 50 mg, 
twice daily, orally after food for 10 days. The efficacy of the study 
drugs was estimated by assessment of pain intensity at baseline and 
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the endpoint using visual analog scale 100 mm (VAS-100mm) [10,11] 
and numerical rating scale (NRS11) [12,13]. At the end of the treatment, 
the relative pain relief was assessed by physician’s global assessment 
and patient’s global assessment (PGA) based on the verbal rating 
scale-5 with the expressions of very good, good, fair, poor, and very 
poor. Any adverse event reported by the patients or observed by the 
physician was monitored during the total duration of the treatment 
for the tolerability of drugs. The data obtained from the study subjects 
were tabulated and expressed as mean±standard deviation, and then 
analyzed using unpaired student’s t-test to compare the means of two 
independent groups and paired t-test to compare the means within the 
group, p<0.05 is considered statistically significant.
RESULTS
Out of 65 enrolled patients, 60 patients completed the study and 
five patients lost to follow-up (2 from Group A and 3 from Group B). 
Demographic data of the study subjects revealed that the mean age of 
study subjects in Group A and Group B was 45.4±8.45 and 46.2±9.7, 
respectively (Table 1).
Efficacy assessments
The pain intensity was assessed by VAS score, it was found that there 
was no significant difference between the two treatment groups, but 
within the groups, there was a significant reduction in pain at baseline 
to at the end of treatment, which was statistically significant (Fig. 1 and 
Table 2).
Fig. 2 and Table 3 represent the pain intensity on the NRS scale at 
baseline and, at the end of the treatment. There was no significant mean 
difference between the two groups, which was statistically insignificant, 
but both the groups showed significant improvements in the reduction 
of pain.
At the end of the study, the patient’s response to the drugs was assessed 
by the PGA (Fig. 3). It was observed that a majority number of patients in 
Group A (95%) experienced a good response compared to Group B (88%).
Assessment of pain relief was done by physician at the end of the study; 
it was observed that major part of 90% of study subjects of Group A had 
good response compared to Group B (78%), (Fig. 4).
Table 4 represents the adverse events (AE) experienced by the study 
subjects at the end of the treatment, no SAE were reported by any of the 
patients in both treatment groups. The majority (70%) of patients of 
Group B reported AE which were mild.
DISCUSSION
LBP is a common musculoskeletal symptom that may either be acute 
or chronic. It is caused due to a variety of diseases and disorders. Age, 
is one of the most common factor in the development of LBP. In most 
studies, it was found that the highest incidence of LBP was in the third 
decade of life, with the prevalence increasing until the age of 60 to 65 
years. However, there is recent evidence that prevalence continues to 
increase with age with more severe forms of LBP. In the present study, 
both groups were comparable with respect to the demographic profile 
of the patients. The mean age of flupirtine and tramadol group was 
45.4±8.45 and 46.2±9.7, respectively. A raised BMI is an established risk 
factor for LBP; in the present study, it was observed there was significant 
rise in mean body mass index (BMI) value. BMI in flupirtine group 
was 28.5±2.9 and in Tramadol group was 29.6±2.2. Similarly, a study 
conducted by Oded et al. found that an increase in BMI was associated 
with an increase in the probability of LBP [14]. Most commonly used 
method for the evaluation of pain severity and relief is the VAS due to its 
practicality, reproducibility, sensitivity to treatment effects, and ease of 
analysis [15]. We have also used VAS for evaluating the severity of pain. 
The current study results are inconsistent with those of a previously 
reported study on the analgesic efficacy of flupirtine versus tramadol. 
A phase IV study conducted by Uberall et al. [16] observed that there 
was a significant reduction of NRS11 scores at baseline and at the end of 
4th week, which is inconsistent with the present study findings. Another 
study conducted by Li et al. [17] found that there was a significant 
reduction of means of VAS and NRS11 scores at baseline and at the end 
of treatment, which is in line with the mean scores of VAS and NRS11 
Table 1: Demography and anthropometric variables of the study 
subjects
Variables Group A, n=30, (%) Group B, n=30, (%)
Gender
Male 8 (26.6) 15 (50)
Female 22 (73.3) 15 (50)
Age (years)
21–30 4 (13.3) 5 (16.6)
31–40 8 (26.6) 12 (40)
41–50 12 (40) 11 (36.6)





Group A: Flupirtine, Group B: Tramadol, SD: Standard deviation
Table 2: Mean VAS score changes within the Groups A and B
Groups Mean±SD p value
Flupirtine group (Group A)
VAS – 100 mm at day 0 60.7±7 0.0001*
VAS – 100 mm at day 10 16.4±10.5
Tramadol group (Group B)
VAS – 100 mm at day 0 62.7±7.7 0.0007*
VAS – 100 mm at day 10 21.1±11.12
VAS: Visual analog scale, SD: Standard deviation, *Statistical significant
Fig. 1: Mean visual analog scale scores of study groups before and 
after treatment. Group A: Flupirtine, Group B: Tramadol
Fig. 2: Mean numerical rating scale scores of study groups before 
and after treatment. Group A: Flupirtine, Group B: Tramadol
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in both groups (p<0.05) but the difference between the groups was 
statistically insignificant. Banerjee and Bhattacharyya [18], in a study 
compared the efficacy and tolerability of flupirtine versus tramadol in 
NSAID intolerant mechanical LBP and used VAS as an efficacy parameter. 
Scores in VAS improved significantly (p<0.05) in both groups in the last 
visit, but more so with flupirtine. No significant group difference in 
mean pain relief scores was found at any point in both groups.
The analgesic agents most commonly used in LBA are prostaglandin 
inhibitors (NSAIDs), COX-2 inhibitors, drugs acting by μ-receptor 
agonist (Opioids), and acetaminophen which has a centrally mediated 
action. Flupirtine is a unique analgesic, centrally acting, and a non-
opioid analgesic which also has an indirect NMDA receptor antagonistic 
action by activating potassium channels. Activation of this channel leads 
to hyperpolarization of neuronal membrane, and the neuron becomes 
less excitable; thus, there is stabilization of resting neuronal membrane. 
This unique potassium channel opening property exhibited by flupirtine 
has not been demonstrated by any other analgesic. Therefore, it belongs 
to a class of drug known as SNEPCO. The drug also possesses a GABA-A 
receptor modulator property [19]. In patients who received tramadol, 
reduction in pain was significant at the end of treatment. Tramadol 
exhibits µ-opioid receptor agonist as well as NE and serotonin reuptake 
inhibitor activity. In the present study, it was observed that nausea, 
vomiting, and sedation were the major adverse effects experienced 
by the patients who received tramadol [20]. No SAE were observed in 
both treatment groups. The majority (70%) of Group B patients had 
reported AE. Most of the AE were mild in severity. An overall good 
tolerability and safety profile were observed. Other previous studies 
also observed that oral flupirtine is an effective analgesic with the 
advantage of fewer central nervous system side effects as compared to 
opioids [21]. Limitations of the study are small in sample size and less 
study duration. We did not study geriatric patients (>60 years) since 
the safety of the drug in this age group is not established. Hence, further 
studies are required in a larger sample and longer study duration to 
evaluate better efficacy and tolerability of study drugs.
CONCLUSION
The results of the current study showed that flupirtine provided an 
analgesic efficacy that was not inferior to that of tramadol. Flupirtine 
was well tolerated, as it is devoid of adverse effects such as nausea, 
vomiting, and sedation, whereas these events are reported tramadol. 
Hence, flupirtine can be used as an alternative drug to opioids as an 
analgesic in the management of moderate chronic LBP.
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